![Nicholas Smith](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 482 884 $ al 31/05/2026
Nicholas Smith is currently Chief Financial & Business Officer at Alto Neuroscience, Inc. since 2023.
Formerly, Mr. Smith was VP-Corporate Development & Investor Relations at Aptinyx, Inc. in 2021.
Mr. Smith completed undergraduate education at North Central College.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
ALTO NEUROSCIENCE, INC. 0,07 % | 16/03/2026 | 24.060 ( 0,07 % ) | 482 884 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| ALTO NEUROSCIENCE, INC. | Director Financiero/CFO | 01/11/2022 |
| Empresas | Cargo | Fin |
|---|---|---|
| APTINYX | Contacto de Relaciones con Inversores | 01/09/2021 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 3 |
|---|---|
North Central College
 North Central College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aptinyx, Inc.
 Aptinyx, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops therapies to treat disorders of the brain and nervous system | Health Technology |
Alto Neuroscience, Inc.
 Alto Neuroscience, Inc. BiotechnologyHealth Technology Engages in psychiatric drug development | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
